MIR30C2

Summary

MIR30C2 (microRNA 30c-2, HGNC:31627) is a microRNA gene on chromosome 6q13.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 407032 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31627
Approved symbol	MIR30C2
Name	microRNA 30c-2
Location	6q13
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-30c-2
Ensembl gene	ENSG00000199094
Ensembl biotype	miRNA
Entrez	407032
RNAcentral	URS0000137EDE — miRNA, 72 nt, 7 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362224

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362224 — 1 exons

Exon	Start	End
ENSE00001436987	71376960	71377031

Expression profiles

Bgee: expression breadth broad, 15 present calls, max score 72.02.

Top tissues by expression

15 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
muscle of leg	UBERON:0001383	72.02	gold quality
heart left ventricle	UBERON:0002084	71.57	gold quality
blood	UBERON:0000178	70.09	gold quality
gastrocnemius	UBERON:0001388	64.12	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	57.68	gold quality
putamen	UBERON:0001874	55.97	gold quality
anterior cingulate cortex	UBERON:0009835	55.11	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	54.54	gold quality
left adrenal gland	UBERON:0001234	52.71	gold quality
skin of leg	UBERON:0001511	52.38	gold quality
minor salivary gland	UBERON:0001830	50.67	gold quality
ascending aorta	UBERON:0001496	50.05	gold quality
caudate nucleus	UBERON:0001873	48.76	gold quality
cerebellar hemisphere	UBERON:0002245	47.35	silver quality
adenohypophysis	UBERON:0002196	37.21	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• miR-30c expression was increased during adipogenesis of multipotent adipose-derived stem cells; miRNA target prediction revealed 2 putative direct targets of miR-30c, PAI-1 and ALK2, both inversely regulated to miR-30c during adipogenesis and responsive to miR-30c overexpression (PMID:21878751)
• growth factor induced proliferation mediates a neutralizing response by significantly increasing miR-30c-2* which reduces BCL9 expression and cell proliferation in SKOV-3 and OVCAR-3 cells (PMID:22024689)
• Expression analysis detected that rs928508 AA showed a significantly increased level of mature miR-30c compared with GG or AG/GG genotype (PMID:22108846)
• the first link between an miRNA and direct regulation of the ER stress response and reveal a novel molecular mechanism by which the PERK pathway, via miR-30c-2*, influences the scale of XBP1-mediated gene expression and cell fate in the UPR. (PMID:22431749)
• Both miR-421 and miR-30c directly interacted with PAI-1 mRNA to inhibit the expression of the associated protein. (PMID:22952991)
• Data indicate that miR-30b/c and miR-21 target respectively the 3’ untranslated region of caspase-3 and TAp63 mRNAs. (PMID:22964638)
• MIR-30c plays a key role in radiation-induced cell damage through regulation of REDD1 expression. (PMID:23144934)
• An interleukin-6 family member, interleukin-11 is identified as a secondary target of twinfilin 1 in the microRNA-30c signalling pathway. (PMID:23340433)
• hypoxia induces epithelial-mesenchymal transition in renal cell carcinoma cells through downregulation of miR-30c, which leads to subsequent increase of Slug expression and repression of E-cadherin production. (PMID:24112779)
• Our data indicated the involvement of miR-30c in PCa progression and suggested its potential role as an independent predictor of biochemical recurrence in PCa. (PMID:24452717)
• validation of a class of serum miR-30c that could act as novel non-invasive biomarkers for diagnosis of Polycystic ovary syndrome (PCOS); miR-30c may be involved in the pathogenesis of PCOS. (PMID:24802714)
• Aberrant miR30c expression alters the expression levels of markers (Ecadherin, snail and vimentin) of epithelial mesenchymal transition. (PMID:25119247)
• Data indicate that combinations of microRNAs let-7c, miR-30c, miR-141, miR-375, and prostate-specific antigen (PSA) obtained better discrimination than PSA alone as noninvasive diagnostic biomarkers for screening of prostate cancer (PC). (PMID:25521481)
• miR-30c plays an important role in lipid metabolism, adipogenesis, and cell proliferation and differentiation. [Review] (PMID:25692340)
• MicroRNA-30c-2-3p negatively regulates NF-kappaB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. (PMID:25732226)
• We describe novel ABCC9 variants in human brain, corresponding to altered 3’UTR length, which could lead to targeting by miR-30c (PMID:26115089)
• Data suggest that after the expression of activating transcription factor 3 (ATF3) and microRNA miR-30c-2-3p elicited by lysophosphatidic acid, miR-30c-2-3p negatively regulates the expression of ATF3 through post-transcriptional silencing. (PMID:26418018)
• MiR-30c-2* is suppressed by human papillomavirus 16/18 E6 protein and contributed to tumor recurrence and drug resistance via increased MTA-1 expression in non-small cell lung cancer. (PMID:27506865)
• urinary biomarker for ischemia-reperfusion-induced kidney injury (PMID:28056546)
• Our study shows that genomic imbalances are involved in miR-30c and let-7a deregulation. One can reasonably assume that dysregulation of these miRNAs is a cause leading to HMGA2 upregulation in ovarian tumors. (PMID:28423547)
• Identify miR-30c as a specific correlate of pulmonary manifestations of TB, potentially involved in the altered glucocorticoid sensitivity observed in these patients. (PMID:28610790)
• Reduction of miR-30c-5p in microparticles as a promoter of early atherosclerosis, by conveying pro-inflammatory pro-apoptotic signals and impairing endothelial healing. (PMID:29016810)
• MiR-30c inhibits ESCC biological behaviors and EMT progress by directly binding to the 3’-UTR of SNAI1. (PMID:29304493)
• Overexpressed miR-30c could weaken osteosarcoma cell’s abilities of viability, proliferation, migration and invasion. MiR-30c could play an important role in tumor suppression for pediatric osteosarcoma progression and metastasis by targeting SOX9 in vitro. (PMID:29364496)
• miR-30c suppressed the proliferation, migration, and invasion of GBM cells via targeting SOX9. (PMID:29495977)
• Serum miR-30c level is elevated during bevacizumab chemotherapy, which is probably an early detection biomarker for predicting cardiotoxicity in NSCLC patients treated with drug chemotherapy. (PMID:29737469)
• Overexpression of miR-30c-2-3p inhibited breast cancer cells migration and invasion. Low expression of miR-30c-2-3p was correlated with poor overall survival. (PMID:30182731)
• Upregulated LncRNA-CCAT1 promotes hepatocellular carcinoma progression by functioning as miR-30c-2-3p sponge. (PMID:30773676)
• miR-103a-2-5p/miR-30c-1-3p inhibits the progression of prostate cancer resistance to androgen ablation therapy via targeting androgen receptor variant 7. (PMID:30963631)
• MiR-30c exerts tumor suppressive functions in colorectal carcinoma by directly targeting BCL9. (PMID:31081087)
• Urinary exosome miR-30c-5p as a biomarker of clear cell renal cell carcinoma that inhibits progression by targeting HSPA5. (PMID:31342628)
• LINC01342 promotes the progression of ovarian cancer by absorbing microRNA-30c-2-3p to upregulate HIF3A. (PMID:31595977)
• the miR-30c/TWF1 axis may have a role in pancreatic cancer progression (PMID:31754292)
• LncRNA RP11-361F15.2 promotes osteosarcoma tumorigenesis by inhibiting M2-Like polarization of tumor-associated macrophages of CPEB4. (PMID:31904478)
• Expression of micro-RNA hsa-miR-30c-5p and hsa-miR-138-1 in renal cell carcinoma. (PMID:32602286)
• Long non-coding RNA CASC7 is associated with the pathogenesis of heart failure via modulating the expression of miR-30c. (PMID:32860492)
• MiR-30c-5p regulates adventitial progenitor cells differentiation to vascular smooth muscle cells through targeting OPG. (PMID:33468212)
• MiR-30c-5p Directly Targets MAPK1 to Regulate the Proliferation, Migration and Invasion of Adenomyotic Epithelial Cells in Adenomyosis. (PMID:33775270)
• Embryo morphokinetic score is associated with biomarkers of developmental competence and implantation. (PMID:33821429)
• miR-30c inhibits angiogenesis by targeting delta-like ligand 4 in liver sinusoidal endothelial cell to attenuate liver fibrosis. (PMID:33861889)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	dre-mir-30c	ENSDARG00000080952
danio_rerio	dre-mir-30b	ENSDARG00000083528
mus_musculus	Mir30c-2	ENSMUSG00000065567
rattus_norvegicus	Mir30c2	ENSRNOG00000035562

Paralogs (5): MIR30E (ENSG00000198974), MIR30D (ENSG00000199153), MIR30B (ENSG00000207582), MIR30A (ENSG00000207827), MIR30C1 (ENSG00000207962)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.